To our knowledge, we for the first time demonstrated that the AKT/mTOR signaling pathway was significantly overactivated and mTORC1 rather than mTORC2 was inhibited by rapamycin in the early phase of cirrhotic portal hypertension in rats (Figure 9). The gene discussed is MTOR; the disease is liver disorder.